Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $2.5 million.

  • Celldex Therapeutics' Other Non-Current Liabilities fell 2677.8% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 2677.8%. This contributed to the annual value of $3.5 million for FY2024, which is 2112.2% down from last year.
  • As of Q3 2025, Celldex Therapeutics' Other Non-Current Liabilities stood at $2.5 million, which was down 2677.8% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Other Non-Current Liabilities registered a high of $10.5 million during Q1 2022, and its lowest value of $2.5 million during Q1 2025.
  • Its 5-year average for Other Non-Current Liabilities is $4.9 million, with a median of $4.4 million in 2023.
  • As far as peak fluctuations go, Celldex Therapeutics' Other Non-Current Liabilities tumbled by 6093.38% in 2021, and later skyrocketed by 7114.32% in 2022.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Other Non-Current Liabilities stood at $7.4 million in 2021, then fell by 27.48% to $5.3 million in 2022, then fell by 17.44% to $4.4 million in 2023, then dropped by 21.12% to $3.5 million in 2024, then decreased by 26.78% to $2.5 million in 2025.
  • Its Other Non-Current Liabilities stands at $2.5 million for Q3 2025, versus $2.5 million for Q2 2025 and $2.5 million for Q1 2025.